Concepedia

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

Kōichi Goto, Yuichiro Ohe, Taro Shibata, Takashi Seto, Toshiaki Takahashi, Kazuhiko Nakagawa, Hiroshi Tanaka, Koji Takeda, Makoto Nishio, Kiyoshi Mori,

The Lancet Oncology · 2016 · 147 citations · 34 references

Concepts

Second-line TreatmentMedicineRandomised Phase 3Metronomic TherapyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologySmall-cell Lung CancerLung CancerRadiologyHealth Sciences

References

34

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Stuart Pocock, Richard Simon · Biometrics · 1975 · 2.3K citations

Prognostic Factors, Sequential Treatment Assignment, Patient Selection +19

Discrete sequential boundaries for clinical trials

K. K. Gordon Lan, David L. DeMets · Biometrika · 1983 · 1.7K citations

Decision Time, Engineering, Clinical Endpoint +16

Discrete Sequential Boundaries for Clinical Trials

K. K. Gordon Lan, David L. DeMets · Biometrika · 1983 · 1.7K citations

Clinical Trial Management, Clinical Endpoint, Clinical Trials +7

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

Kazumasa Noda, Yutaka Nishiwaki, Masaaki Kawahara et al. · New England Journal of Medicine · 2002 · 1.4K citations · Full text

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd et al. · Journal of Clinical Oncology · 1999 · 943 citations